Compare AstraZeneca plc (AZN) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? AstraZeneca plc trades at $158.47 (market cap $248.14B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.98. The key difference: AstraZeneca plc pays a 2.01% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | JEPQ | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $61.46 |
52-Week Low | $147.06 | $53.77 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.
Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
